Clinical Trial Update: A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating a multipeptide vaccine combined with toll-like receptor agonists in melanoma patients; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Multipeptide vaccine (multipeptide vaccine)
• Toll-like receptor agonists (TLR agonists)

Snippet

Sponsor: Craig L Slingluff, Jr | Conditions: Melanoma | Phase 1 | Status: COMPLETED